Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
791.74
-12.16 (-1.51%)
Streaming Delayed Price
Updated: 1:28 PM EDT, Sep 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
247,113
Open
805.23
Bid (Size)
791.39 (40)
Ask (Size)
792.35 (40)
Prev. Close
803.90
Today's Range
790.02 - 813.53
52wk Range
541.00 - 859.34
Shares Outstanding
91,779,465
Dividend Yield
0.47%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
↗
Today 12:03 EDT
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...
Via
MarketBeat
Topics
ETFs
Is Regeneron Stock a Bargain Below $800?
↗
September 22, 2026
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Via
The Motley Fool
Topics
Intellectual Property
Performance
YTD
+2.0%
+2.0%
1 Month
-4.4%
-4.4%
3 Month
+28.1%
+28.1%
6 Month
+6.7%
+6.7%
1 Year
+32.9%
+32.9%
More News
Read More
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
September 22, 2026
Via
StockStory
Topics
Stocks
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
September 15, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
↗
September 09, 2026
Via
Chartmill
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
↗
September 14, 2026
Via
MarketBeat
Topics
Intellectual Property
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 14, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
↗
September 12, 2026
Via
MarketBeat
Topics
ETFs
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 11, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
September 10, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
September 10, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 10, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Deadline
September 08, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
September 08, 2026
Via
StockStory
Topics
Stocks
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 07, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
↗
September 04, 2026
Via
The Motley Fool
Topics
Intellectual Property
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
September 04, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 03, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
↗
September 02, 2026
Via
Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
September 02, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
September 01, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 31, 2026
From
Schall, Brown & Schwartz LLP
Via
GlobeNewswire
Frequently Asked Questions
Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 791.74
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 09/23/26 01:28 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 72.67B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 73B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today